Cargando…
Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis
AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left mai...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669294/ https://www.ncbi.nlm.nih.gov/pubmed/36407423 http://dx.doi.org/10.3389/fcvm.2022.1028007 |
_version_ | 1784832066906488832 |
---|---|
author | Pan, Liang Lu, Wenjie Han, Zhanying Pan, Sancong Wang, Xi Shan, Yingguang Peng, Meng Qin, Xiaofei Sun, Guoju Zhang, Peisheng Dong, Jianzeng Qiu, Chunguang |
author_facet | Pan, Liang Lu, Wenjie Han, Zhanying Pan, Sancong Wang, Xi Shan, Yingguang Peng, Meng Qin, Xiaofei Sun, Guoju Zhang, Peisheng Dong, Jianzeng Qiu, Chunguang |
author_sort | Pan, Liang |
collection | PubMed |
description | AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left main (LM) true bifurcation lesion. We compared clinical and angiographic outcomes of hybrid [DCB + drug-eluting stent (DES)] versus DES-only strategy (provisional stenting or two-stent strategies) in de novo LM true bifurcated lesions. METHODS: The primary endpoint was the 2-year composite rate of target lesion failure (TLF): cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target lesion revascularization (CD-TLR). A routine 1-year angiographic follow-up was scheduled. Propensity-score matching was utilized to assemble a cohort of patients with similar baseline characteristics. RESULTS: Among 1077 eligible patients, 199 who received DCB treatment and 398 who were assigned to DES therapy had similar propensity scores and were included in the analysis. TLF within 2 years occurred in 13 patients (7.56%) assigned to DCB group, and 52 patients (14.36%) assigned to DES group (odds ratio: 0.487; 95% confidence interval: 0.258–0.922; P = 0.025; Log-rank P = 0.024). Compared with the DES group, the DCB group resulted in a lower rate of CD-TLR (2.91% vs. 9.42%; P = 0.007). Cardiac death, TVMI, all-cause mortality, and stent thrombosis were comparable between both groups. Patients treated with DES-only were associated with a higher late lumen loss (0.42 ± 0.62 mm vs. 0.13 ± 0.42 mm, P < 0.001) compared with the DCB group at 1 year. In sensitivity analysis, the DCB group also presented a lower incidence of TLF, CD-TLR and stent thrombosis both compared to the two-stent strategy and compared to provisional stenting (Ps < 0.05). CONCLUSION: The 2-year results of PCI utilizing DCB for LM true bifurcation lesions are superior to employing DES alone in terms of safety and effectiveness. |
format | Online Article Text |
id | pubmed-9669294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96692942022-11-18 Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis Pan, Liang Lu, Wenjie Han, Zhanying Pan, Sancong Wang, Xi Shan, Yingguang Peng, Meng Qin, Xiaofei Sun, Guoju Zhang, Peisheng Dong, Jianzeng Qiu, Chunguang Front Cardiovasc Med Cardiovascular Medicine AIMS: An increasing body of evidence suggests that drug-coated balloon (DCB) angioplasty represents a valuable option for revascularization in selected patients with coronary bifurcation disease. However, there remains a paucity of real-world observational evidence on the efficacy of DCB in left main (LM) true bifurcation lesion. We compared clinical and angiographic outcomes of hybrid [DCB + drug-eluting stent (DES)] versus DES-only strategy (provisional stenting or two-stent strategies) in de novo LM true bifurcated lesions. METHODS: The primary endpoint was the 2-year composite rate of target lesion failure (TLF): cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target lesion revascularization (CD-TLR). A routine 1-year angiographic follow-up was scheduled. Propensity-score matching was utilized to assemble a cohort of patients with similar baseline characteristics. RESULTS: Among 1077 eligible patients, 199 who received DCB treatment and 398 who were assigned to DES therapy had similar propensity scores and were included in the analysis. TLF within 2 years occurred in 13 patients (7.56%) assigned to DCB group, and 52 patients (14.36%) assigned to DES group (odds ratio: 0.487; 95% confidence interval: 0.258–0.922; P = 0.025; Log-rank P = 0.024). Compared with the DES group, the DCB group resulted in a lower rate of CD-TLR (2.91% vs. 9.42%; P = 0.007). Cardiac death, TVMI, all-cause mortality, and stent thrombosis were comparable between both groups. Patients treated with DES-only were associated with a higher late lumen loss (0.42 ± 0.62 mm vs. 0.13 ± 0.42 mm, P < 0.001) compared with the DCB group at 1 year. In sensitivity analysis, the DCB group also presented a lower incidence of TLF, CD-TLR and stent thrombosis both compared to the two-stent strategy and compared to provisional stenting (Ps < 0.05). CONCLUSION: The 2-year results of PCI utilizing DCB for LM true bifurcation lesions are superior to employing DES alone in terms of safety and effectiveness. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669294/ /pubmed/36407423 http://dx.doi.org/10.3389/fcvm.2022.1028007 Text en Copyright © 2022 Pan, Lu, Han, Pan, Wang, Shan, Peng, Qin, Sun, Zhang, Dong and Qiu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Pan, Liang Lu, Wenjie Han, Zhanying Pan, Sancong Wang, Xi Shan, Yingguang Peng, Meng Qin, Xiaofei Sun, Guoju Zhang, Peisheng Dong, Jianzeng Qiu, Chunguang Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title | Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title_full | Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title_fullStr | Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title_full_unstemmed | Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title_short | Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis |
title_sort | drug-coated balloon in the treatment of coronary left main true bifurcation lesion: a patient-level propensity-matched analysis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669294/ https://www.ncbi.nlm.nih.gov/pubmed/36407423 http://dx.doi.org/10.3389/fcvm.2022.1028007 |
work_keys_str_mv | AT panliang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT luwenjie drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT hanzhanying drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT pansancong drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT wangxi drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT shanyingguang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT pengmeng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT qinxiaofei drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT sunguoju drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT zhangpeisheng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT dongjianzeng drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis AT qiuchunguang drugcoatedballooninthetreatmentofcoronaryleftmaintruebifurcationlesionapatientlevelpropensitymatchedanalysis |